Cryosite posts record half-year results and doubles capacity with new facility

Cryosite Limited ( (AU:CTE) ) just unveiled an announcement.

Cryosite reported record first-half FY26 revenue of $8.3 million, up 25% year on year, with EBITDA rising 33% to $2.0 million as margins expanded and operating leverage improved. Growth was broad-based across ambient, cold and frozen, and ultra-frozen and cryogenic services, with volumes up 30%, while higher utilisation and disciplined capital deployment translated into a 36% lift in net profit after tax.

The company strengthened its balance sheet with solid operating cash flow and ended January with $3.14 million in cash, underscoring the cash-generative nature of its model. Completion of the Adderley Street freehold facility in Auburn more than doubles warehousing and storage capacity, enhances dual-site resilience for clients, and positions Cryosite to capture rising demand in biologics, cell and gene therapies and regulated pharmaceutical handling.

The most recent analyst rating on (AU:CTE) stock is a Buy with a A$1.50 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.

More about Cryosite Limited

Cryosite Limited is an Australian specialist in temperature-controlled logistics and storage, serving clinical trials, commercial pharmaceuticals and biologics. Its operations span ambient, cold, frozen, ultra-frozen and cryogenic storage, including cord blood banking, with growing exposure to cell and gene therapies and mRNA-based medicines.

Average Trading Volume: 3,981

Technical Sentiment Signal: Buy

Current Market Cap: A$58.57M

For an in-depth examination of CTE stock, go to TipRanks’ Overview page.